EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitFallberichtOpen Access · CC BY-NC-ND 4.0

Omalizumab in the treatment of Morbihan syndrome in an adolescent girl – case report and literature review

Zofia Mazurek-Durlak, Katarzyna Mularczyk, Przemko Kwinta, Grzegorz Lis, Ewa Cichocka-Jarosz

Allergologia et Immunopathologia · 2023

DOI: 10.15586/aei.v52i2.978 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Allergologia et Immunopathologia, 2023. Verfasst von Zofia Mazurek-Durlak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Pediatrics, Jagiellonian University Medical College, 265, Wielicka Str. 30-663 Krakow, Poland; zofia.mazurek@gmail…. Hauptthemen laut MEDLINE: Rosacea, Angioedema. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Morbihan syndrome (MS) is characterized by solid facial edema, usually related to rosacea or acne vulgaris. The facial edema deforms the patient’s features, can impair peripheral vision, and affects quality of life. Its pathophysiology remains unclear. The disease usually has a slow and chronic course. MS most commonly affects middle-aged Caucasian men with rosacea and is rare in people below 20 years of age. MS is a diagnosis of exclusion. There is no standard treatment for MS, though systemic isotretinoin and antihistamines are mainly used. We present the case of an adolescent girl with MS nonresponding to 19 months of isotretinoin treatment with add-on antihistamines. Therapy with monthly administration of omalizumab (anti-IgE) for 6 months was an effective therapeutic option, improving the quality of life. Our case is the second description of omalizumab use in Morbihan syndrome, the first in an adolescent.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RosaceaAngioedemaMaleMiddle AgedFemaleHumansAdolescentIsotretinoinOmalizumabQuality of LifeSyndromeEdemaHistamine Antagonists

Stichwörter der Autor:innen

AdolescentMorbihan syndromeanti-IgEomalizumabsolid facial edema

Substanzen

IsotretinoinOmalizumabHistamine Antagonists

Autor:innen und Institutionen

  • Faculty of Medicine, Department of Pediatrics, Jagiellonian University Medical College, 265, Wielicka Str. 30-663 Krakow, Poland; zofia.mazurek@gmail.com.
  • Faculty of Medicine, Department of Pediatrics, Jagiellonian University Medical College, 265, Wielicka Str. 30-663 Krakow, Poland.

Zitieren

APA

Mazurek-Durlak, Z., Mularczyk, K., Kwinta, P., Lis, G., & Cichocka-Jarosz, E. (2023). Omalizumab in the treatment of Morbihan syndrome in an adolescent girl – case report and literature review. Allergologia et Immunopathologia. https://doi.org/10.15586/aei.v52i2.978

Vancouver

Mazurek-Durlak Z, Mularczyk K, Kwinta P, Lis G, Cichocka-Jarosz E. Omalizumab in the treatment of Morbihan syndrome in an adolescent girl – case report and literature review. Allergologia et Immunopathologia. 2023. doi:10.15586/aei.v52i2.978

BibTeX
@article{MazurekDurlak2023,
  author = {Mazurek-Durlak, Zofia and Mularczyk, Katarzyna and Kwinta, Przemko and Lis, Grzegorz and Cichocka-Jarosz, Ewa},
  title = {Omalizumab in the treatment of Morbihan syndrome in an adolescent girl – case report and literature review},
  journal = {Allergologia et Immunopathologia},
  year = {2023},
  doi = {10.15586/aei.v52i2.978}
}
Kostenlos starten →